MEI Pharma, Inc. (NASDAQ:MEIP) has scheduled a conference call for 9th September 2020 at 5:00 PM Eastern Time to announce its 4Q20 financial results.
The conference call will also be webcast live under the investor relations section of the website www.meipharma.com
Earnings Expectation
MEI Pharma, Inc. is expected to report fourth quarter earnings results, after market close, on Wednesday 9th September 2020. Analysts polled by Thomson Reuters anticipate fourth quarter income of $ 0.21 per share. Looking ahead, the full year loss are expected at $ 0.05 per share on the revenues of $ 48.42 million.
MEI Pharma, Inc., a pharmaceutical company, focuses on the clinical development of novel therapies for the treatment of cancer. The companys clinical drug candidate includes Pracinostat, an oral available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes ME-401, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia or follicular lymphoma; ME-344, an isoflavone-derived mitochondrial inhibitor for the treatment of HER2-negative breast cancer; and Voruciclib, an oral cyclin-dependent kinase inhibitor.
